Osteopontin is required for the maintenance of leukemia stem cells in acute myeloid leukemia

Acute myeloid leukemia (AML) is a heterogeneous hematopoietic disorder with a poor prognosis. The clinical significance of Leukemia stem cells (LSCs) plays an important role in the generation of AML and is the main cause of the recurrence after remission. Osteopontin (OPN), an extracellular matrix protein, has been implicated in hematopoietic malignancies. However, the specific role and the underlying mechanism of AML cell autocrined OPN in leukemia maintenance remain unknown. Here, we showed that knockdown of Opn expression significantly prolonged the survival of mice with MLL-AF9 cell-induced AML and markedly reduced the tumor burden. The LSCs from the Opn-knockdown groups exhibited decreased numbers and impaired function as determined by immunophenotype, colony-forming and limiting dilution assays. Further analysis revealed that Opn prevents LSCs from undergoing apoptosis and cell cycle arrest. Repression of OPN in human AML cell lines in vitro mimics the phenotypes observed in the mouse model. Overall, our data indicated that OPN is a potent therapeutic target for eradicating LSCs in AML. (c) 2022 Elsevier Inc. All rights reserved.

Automated summary

This study reveals the crucial role of osteopontin (OPN) in acute myeloid leukemia (AML), showing that OPN contributes to the maintenance of leukemia stem cells (LSCs) by preventing apoptosis and cell cycle arrest. Therefore, OPN could be a potential therapeutic target for AML treatment.